News

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.

Experts discuss real-world strategies for managing alopecia areata, emphasizing JAK inhibitors, psychosocial impacts, and personalized patient care approaches.

What were the top dermatology hits of 2025?

In part 3 of this Case-Based Roundtable supplement, experts discuss psoriatic therapies for hair-baring areas.

Omar Noor, MD, recently presented 3 cases of psoriasis in older patients at Horizons in Advanced Practice to discuss available treatment options and considerations for Medicare and in-office injections.

A study reveals stress coping strategies and eosinophil levels impact CU in adolescents, highlighting the need for integrated psychological support.

Explore the risks of bypassing dermatologists for DIY skincare and telehealth treatments, highlighting real patient experiences and expert insights.

Zasocitinib emerges as a promising oral therapy for psoriasis, achieving significant skin clearance and favorable safety in recent phase 3 trials.

At a recent Case-Based Roundtable event, Aaron Farberg, MD, moderated a discussion of challenging atopic dermatitis cases spanning adult, adolescent, and pediatric patients.

In part 2 of this supplement, experts discuss therapies for inflammatory acne

Porter leads a dynamic roundtable on hidradenitis suppurativa, exploring innovative treatments and collaborative strategies for improved patient outcomes.

Early-phase development introduces a potential first-in-class oral approach targeting type 2 inflammation relevant to dermatologic diseases.

Soligenix reveals promising results from its phase 2a study of SGX302, a novel therapy for mild-to-moderate psoriasis, enhancing patient experience and efficacy.

New research reveals that combining DecisionDx-UM and PRAME significantly enhances survival predictions for uveal melanoma.

Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.

This review of the latest dermatologic studies includes case studies on allergic contact dermatitis from UV nail polish, the introduction of the visual aesthetics methodology, a review of topical timolol, and more.

An expert panel endorses Castle Biosciences’ 31-GEP test, enhancing melanoma management through personalized risk assessment and improved prognostic accuracy.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed psoriasis in high-impact sites, overall psoriatic disease, and available therapies.

Wildfire air pollution significantly increases atopic dermatitis and itch-related dermatologic visits, highlighting the urgent need for skin protection during poor air quality.

In part 2 of this Case-Based Roundtable supplement, experts discuss therapeutic options for psoriasis when considering involvement of special areas.

In part 1 of this supplement, experts discuss current and emerging treatments for patients, considering lifestyle choices.

A bentonite and Alcea sulphurea facial mask significantly improved acne severity and patient satisfaction in a recent clinical trial.

GT20029 shows promising results in treating androgenetic alopecia, enhancing hair density with minimal adverse effects in men after 12 weeks.

Topline results are expected in the first quarter of 2026.

In part 1 of this Case-Based Roundtable supplement, experts discuss biologic treatment options for psoriasis, and balancing efficacy with patient needs.

The BLA is supported by phase 3 data demonstrating rapid skin clearance and sustained disease control in patients with GPP.

Experts discuss innovative, steroid-sparing treatments for pediatric atopic dermatitis, emphasizing personalized care and proactive management strategies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.